The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Novel formulations of taxanes: a review. Old wine in a new bottle?
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wani, M. C., Taylor, H. L., Wall, M. E., Coggon, P., & McPhail, A. T. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00738a045 · Cited by 4,073
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Central Nervous System Toxicity after Liver Transplantation
de Groen, P. C., Aksamit, A. J., Rakela, J., Forbes, G. S., & Krom, R. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710013171404 · Cited by 498
Cited by
Insoluble drug delivery strategies: review of recent advances and business prospects
Kalepu, S., & Nekkanti, V. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.003 · Cited by 1,410
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
“Given the drawbacks resulting from the use of CrEL as a solubilizer, new CrEL-free formulations of paclitaxel are of great interest for development in clinical use [9].”
BackgroundTalelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Gubernator, J. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.566552 · Cited by 325
Improvement of drug safety by the use of lipid-based nanocarriers
Lim, S. B., Banerjee, A., & Önyüksel, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.002 · Cited by 324
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs
Luxenhofer, R., Schulz, A., Roques, C., Li, S., Bronich, T. K., Batrakova, E. V., Jordan, R., & Kabanov, A. V. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.057 · Cited by 286
Barbuti, A., & Chen, Z.-S. (2015) · Cancers · doi:10.3390/cancers7040897 · Cited by 269
Polymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs
Shin, H.-C., Alani, A. W. G., Rao, D. A., Rockich, N. C., & Kwon, G. S. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.024 · Cited by 243
A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs
Shin, H.-C., Alani, A. W. G., Cho, H., Bae, Y., Kolesar, J. M., & Kwon, G. S. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000549 · Cited by 126
Han, Y., He, Z., Schulz, A., Bronich, T. K., Jordan, R., Luxenhofer, R., & Kabanov, A. V. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300159u · Cited by 125
He, Z., Schulz, A., Wan, X., Seitz, J., Bludau, H., Alakhova, D. Y., Darr, D. B., Perou, C. M., Jordan, R., Ojima, I., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.024 · Cited by 99
Danquah, M., Fujiwara, T., & Mahato, R. I. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.11.081 · Cited by 101
Seo, Y., Schulz, A., Han, Y., He, Z., Bludau, H., Wan, X., Tong, J., Bronich, T. K., Sokolsky, M., Luxenhofer, R., et al. (2015) · Polymers for Advanced Technologies · doi:10.1002/pat.3556 · Cited by 67
Wang, T., Yang, S., Mei, L. A., Parmar, C. K., Gillespie, J. W., Praveen, K. P., Petrenko, V. A., & Torchilin, V. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0052 · Cited by 35
“one of the most active agents used for the treatment of metastatic breast cancer (2).”
BackgroundMa, W. W., Zhu, M., Lam, E. T., Diamond, J. R., Dy, G. K., Fisher, G. A., Goff, L. W., Alberts, S., Bui, L. A., Sanghal, A., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04235-z · Cited by 12
Metadata
- Authors
- Hennenfent, K. L., & Govindan, R.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2006-05
- Volume
- 17
- Issue
- 5
- Pages
- 735-749
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2136447069
- Cited by
- 345
- References
- 65
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.